Effects of cyproheptadine on body weight gain in children with nonorganic failure to thrive in Taiwan: A hospital-based retrospective study

Failure to thrive (FTT) impairs the expected normal physical growth of children. This study aimed to evaluate the effects of cyproheptadine hydrochloride on growth parameters in prepubertal children with FTT. The medical records of prepubertal children who were newly diagnosed with FTT at China Medical University Hospital between 2007 and 2016 were retrospectively examined. The patients were divided into two groups depending on whether they had (T-group) or had not (NT-group) received cyproheptadine hydrochloride (0.3 mg/kg daily) for at least 14 days. The mean length of the treatment period was 97.22 days (range: 14–532 days). Weight, height, and body mass index were adjusted for age using the median values in the growth charts for Taiwanese boys and girls as the reference. A total of 788 patients aged 3–11 years were enrolled, 50 in the T-group and 738 in the NT-group. No statistically significant difference in the median age-adjusted weight value was noted between the T-group and NT-group during the follow up period. In the T-group, age-adjusted weight and body mass index were inversely associated with age (P <0.001, P <0.001) and positively associated with medication duration (P = 0.026, P = 0.04). Our findings underscore the positive association between cyproheptadine hydrochloride treatment and weight gain among prepubertal children. Further prospective clinical studies with a. longer and consistent treatment course is warranted.

Estimation of Cyproheptadine Hydrochloride and Tricholine Citrate Simultaneously in Syrup Dose by Applying Stability Indicating HPLC Methodology

An stability indicating HPLC methodology for the concurrent estimation of Tricholine citrate (TRC) and Cyproheptadine hydrochloride (CYH) in syrup dose and bulk using Waters column reverse phase C18 (5 µm, 250 mm and 4.6 mm) as stationary phase and 0.1M Na2HPO4 of pH 4.5 and acetonitrile in proportion of 60:40 (v/v) at flow of 1.0 ml/min rate as mobile phase was reported. The linear scales were 275-825 μg/ml for TRC and 2-6 μg/ml for CYH with correlation coefficients of 0.9999 for TRC and 0.9997 for CYH. Followed ICH Q2(R1) strategies for validating the suggested method for precision, sensitivity, robustness, specificity, selectivity and accuracy. The measures of LOD and LOQ are 0.023 µg/ml and 0.079 µg/ml for CYH, while for TRC it was 0.565 µg/ml and 1.885 µg/ml, respectively. The precision measures for CYH and TRC were 0.073 and 0.212 relative measured deviation percentage, respectively. The accuracy measures for CYH and TRC were 99.40% and 99.09% mean assay percentiles, respectively. Recovery percentiles measures of CYH and TRC were ranged between 99.48% to 100.35% and 100.38% and 100.41%, respectively. While in degradation investigation, peaks of degraded products are very well differentiated from TRC and CYH peaks suggesting the specificity and stability of suggested methodology. The results permit the application of the proposed stability indicating HPLC methodology in syrup dose forms.

In silico and in vitro studies of the inhibitory effect of antihistamine drug Cyproheptadine hydrochloride on human salivary alpha amylase.

Background: For the first time, the inhibitory effects on human salivary alpha-amylase activity of the antiinflammatory drugs: indomethacin, diclofenac sodium, ketoprofen, diclofenac potassium, diclofenac, triamcinolone acetonide and the antihistamines drugs: levocetirizine dihydrochloride, desloratadine, cycloheptadine hydrochloride has been investigated to confirm the other properties of these drugs. Objective: This study aimed to determine the effect of nine known drugs on human salivary α-amylase in vitro and the nature of interactions with structure-activity relationship using molecular docking Method: The inhibition of human salivary alpha amylase by the six anti-inflammatory and three antihistamines drugs has been carried out using the new method that has been proved in our previous work. Molecular docking has been achieved for the first time for these drugs using AutoDock Vina program. Results: The Cyproheptadine hydrochloride presented the highest inhibitory activity against α-amylase with IC50=0.7 mg/ml, while the other drugs show weak activities (IC50 > 2 mg/ml). Conclusion: We conclude that Cyproheptadine hydrochloride and which studied by docking experiments exhibited the best inhibitory activity on salivary α-amylase in vitro & in silico.